.jpg)
Oct 28
Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
Melbourne, Australia – 28 October 2024: Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies...